First published 9/28/2026, 6:57:15 AM · Last updated 9/28/2026, 6:57:15 AM

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase <scp>III</scp> , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

A Wiley-published journal article (11 May 2026) reports a Phase III multicenter, double-blind, active-controlled non-inferiority trial comparing elagolix and dienogest for treating moderate-to-severe endometriosis pain.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 3/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study compares two medical treatments for moderate-to-severe endometriosis pain and may inform clinical decisions.

Sources

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase <scp>III</scp> , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

Report an issue